Corcept Therapeutics Inc (CORT)
51.83
-2.96
(-5.40%)
USD |
NASDAQ |
Nov 15, 16:00
51.83
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Research and Development Expense (TTM): 231.29M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 231.29M |
| June 30, 2024 | 217.47M |
| March 31, 2024 | 202.01M |
| December 31, 2023 | 184.35M |
| September 30, 2023 | 166.40M |
| June 30, 2023 | 154.17M |
| March 31, 2023 | 143.72M |
| December 31, 2022 | 130.99M |
| September 30, 2022 | 122.76M |
| June 30, 2022 | 117.56M |
| March 31, 2022 | 112.96M |
| December 31, 2021 | 113.86M |
| September 30, 2021 | 113.62M |
| June 30, 2021 | 119.40M |
| March 31, 2021 | 117.66M |
| December 31, 2020 | 114.76M |
| September 30, 2020 | 110.80M |
| June 30, 2020 | 99.74M |
| March 31, 2020 | 94.90M |
| December 31, 2019 | 89.02M |
| September 30, 2019 | 83.50M |
| June 30, 2019 | 79.55M |
| March 31, 2019 | 78.44M |
| December 31, 2018 | 75.25M |
| September 30, 2018 | 70.08M |
| Date | Value |
|---|---|
| June 30, 2018 | 62.92M |
| March 31, 2018 | 50.25M |
| December 31, 2017 | 40.38M |
| September 30, 2017 | 33.23M |
| June 30, 2017 | 28.59M |
| March 31, 2017 | 26.39M |
| December 31, 2016 | 23.84M |
| September 30, 2016 | 21.45M |
| June 30, 2016 | 18.01M |
| March 31, 2016 | 15.68M |
| December 31, 2015 | 15.42M |
| September 30, 2015 | 15.12M |
| June 30, 2015 | 14.55M |
| March 31, 2015 | 15.46M |
| December 31, 2014 | 18.37M |
| September 30, 2014 | 21.15M |
| June 30, 2014 | 23.26M |
| March 31, 2014 | 23.50M |
| December 31, 2013 | 20.47M |
| September 30, 2013 | 18.76M |
| June 30, 2013 | 16.61M |
| March 31, 2013 | 14.79M |
| December 31, 2012 | 14.07M |
| September 30, 2012 | 15.86M |
| June 30, 2012 | 16.08M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
89.02M
Minimum
Dec 2019
231.29M
Maximum
Sep 2024
137.87M
Average
118.53M
Median
Research and Development Expense (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 10.82M |
| Madrigal Pharmaceuticals Inc | 281.71M |
| ADMA Biologics Inc | 1.868M |
| Alnylam Pharmaceuticals Inc | 1.098B |
| Akebia Therapeutics Inc | 35.73M |